Supplementary Figures 1 through 8 and Supplementary Tables 1 through 4 from Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT–YB1–MDR1 Signaling Pathway

1. Supplementary Figure S1. PCR-SSCP analysis of 21 exons of human RecQL4 gene in human gastric cancer cell lines. 2. Supplementary Figure S2. PCR-SSCP analysis of 21 exons of human RecQL4 gene in human primary gastric tumors and matched gastric tissue controls. 3. Supplementary Figure S3. DNA sequencing result of exons 2-3 of human RecQL4 gene in AGS and HGC-27 cells. 4. Supplementary Figure S4. Coomassie brilliant blue staining images of purified tagged-proteins expressed in E. Coli. 5. Supplementary Figure S5. YB1 domains specifically interacting with RecQL4. 6. Supplementary Figure S6. Level of YB1 and Akt interaction in cytoplasmic(C) and nuclear (N) fractions from MGC-803/Tet-on/Flag-RecQL4 cells with or without RecQL4 induction. 7. Supplementary Figure S7. Effect of YB1 and RecQL4 on MVP promoter activity. 8. Supplementary Figure S8. In vitro direct binding of YB1 and/ RecQL4 proteins to MDR1 promoter region detected by EMSA analysis. 9. Supplementary Table S1. Clinicopathological characteristics of patients with early gastric adenocarcinomas. 10. Supplementary Table S2. Correlation of RecQL4 nuclear and cytoplasmic expression with clinical parameters of gastric cancer patients. 11. Supplementary Table S3. Primer sets of 21 exons of human RecQL4 gene used for PCR-SSCP analysis. 12. Supplementary Table S4. PCR primer sets of drug resistance related genes used for real time RT-PCR analysis.